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Endogenous ouabainThe hormone aldosterone has a well-recognized physiological role in epithelial ﬂuid and electrolyte
homeostasis, and more recently deﬁned pathophysiological roles in the cardiovascular system. The term
“risk factor” implies an active role in pathophysiology, with levels lower (e.g. HDL) or higher (e.g. LDL, BP)
than normal contributing to an increased likelihood of morbidity and/or mortality. In this regard, primary
aldosteronism represents a classic illustration of aldosterone as a cardiovascular risk factor. In this syndrome
of (relatively) autonomous aldosterone secretion, the effects of elevated hormone levels are on a range of
organs and tissues—the heart, blood vessels and brain, inter alia. In other cardiovascular disorders (e.g. CCF,
EH) while an elevation of aldosterone levels is often regarded as a risk factor, it is more correctly a response
to the severity of disease (or to treatment intervention), rather than necessarily a risk factor with a primary
role in disease progression. An enduring enigma relevant to any discussion of aldosterone as a risk factor is
that very high levels of aldosterone in response to chronic sodium deﬁciency have homeostatic (and
protective of cardiovascular) functions, while the considerably lower levels commonly seen in primary
aldosteronism are incontrovertibly damaging. A ﬁnal section of the paper will thus propose a mechanism
which might solve this enigma, based on the commonalities–and a single crucial difference–in the factors
stimulating the secretion of aldosterone and endogenous ouabain from the zona glomerulosa of the adrenal
gland.+61 3 9594 6125.
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The hormone aldosterone was isolated and characterized in 1953
[1,2] and the syndrome of primary aldosteronism described soon
afterwards [3,4]. Initially the hormone was termed electrocortin,
reﬂecting its mineralocorticoid action on transepithelial electrolyte
transport [5], but soon afterwards by its current name, when its
structure was shown to contain a unique (and highly reactive)
aldehyde (CHO) group instead of the customary methyl (CH3) group,
at carbon 18 of the steroid skeleton. In the adrenal gland aldosterone
is synthesized uniquely in the external layer of the cortex, the zona
glomerulosa; ectopic sites of aldosterone biosynthesis (heart, blood
vessels, brain) have been both reported and disputed [6–11]. The
primary stimuli to aldosterone secretion are angiotensin II, following
the release of renin in response to stress (e.g. hypovolemia) and
posture; equally importantly but often relegated to second place as a
secretagogue, is plasma [K+] in chronic Na+ deﬁciency or K+
loading [12,13]. The homeostatic response to elevation of aldosterone
secretion is restoration of the status quo—sodium and water retention
in hypovolemia and Na+ deﬁciency, kaliuresis in potassium loading,etc. In primary aldosteronism secretion of the hormone is relatively
autonomous, in that although it may remain sensitive to angiotensin II
or potassium status, the turn-off limb of the feedback loop is deﬁcient,
resulting in inappropriate levels for the patient's ﬂuid and electrolyte
status.
Aldosterone acts physiologically at epithelia via intracellular
mineralocorticoid receptors, members of the 49 member (in humans)
steroid/thyroid/retinoid/lipid/orphan receptor superfamily, and of a
closely related subfamily with glucocorticoid receptors, progesterone
receptors and androgen receptors [14]. Early studies on mineralocor-
ticoid receptors showed two puzzling features. First, they were
distributed across a range of extraepithelial tissues, such as brain [15]
and heart [16]. Secondly, they showed equivalently high afﬁnity for
aldosterone–which circulates at very low levels–and the glucocorti-
coids cortisol and corticosterone [15,17], and in addition for
progesterone [18], the potential implications of which are yet to be
established. In epithelia aldosterone-selectivity of mineralocorticoid
receptor activation is procured by co-expression of the enzyme 11β-
hydroxysteroid dehydrogenase [19], which is also expressed in
certain non-epithelial tissues (vascular wall, placenta, nucleus tractus
solitarius), making them similarly physiological aldosterone target
tissues. It was initially thought [19], and is still commonly taught, that
11β-hydroxysteroid dehydrogenase operates by excluding glucocor-
ticoids from protected mineralocorticoid receptors via conversion to
receptor-inactive 11-keto congeners (e.g. cortisol to cortisone). It has
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mineralocorticoid receptors are occupied (~ 90%) but not activated by
normal levels of endogenous glucocorticoids [20]. Mineralocorticoid
receptor–glucocorticoid complexes are presumably held inactive under
normal conditions by the obligate co-generation of high levels of NADH,
shown to be an inhibitor of transcription by co-repressor activation in
other transcriptional systems [21]. Under conditions of tissue damage,
reactive oxygen species generation and intracellular redox change,
cortisol becomes amineralocorticoid receptor agonist, in the vessel wall
[22] and heart [23], mimicking the deleterious effects of elevated
aldosterone inappropriate for salt status.
2. Primary aldosteronism
For 40 years after the ﬁrst report of primary aldosteronism, it was
considered to be a rare (b 1% of hypertensives) and relatively benign
condition, characterized by hypokalaemia, with adrenal mass(es)
visible on imaging or scintigraphy treated by open unilateral
adrenalectomy, and in the absence of lateralization by spironolactone.
Currently primary aldosteronism is recognised as neither rare nor
benign. In terms of prevalence estimates vary considerably, often
reﬂecting patient referral patterns; a consensus ﬁgure is 8–13% of all
hypertensives (and perhaps ~3% of unselected normotensives).
Hypokalaemia is in fact uncommon, being seen in under half of
patients subsequently shown to have an adrenal adenoma, and under
20% of those with autonomous aldosterone secretion from bilateral
hyperplasia. Current guidelines [24] base case detection on an
elevated plasma aldosterone to renin ratio, with the diagnosis
conﬁrmed or excluded on the basis of any one of at least four
different testing procedures. Of the ~10% of hypertensives with
primary aldosteronism diagnosed this way, 3–4% will normally have
unilateral hypersecretion upon lateralization by bilateral adrenal
venous sampling, and the remaining 6–7% bilateral overproduction. In
addition to this ~10%, there is a cohort of patients who show “resistant
hypertension,”with blood pressure remaining high despite 3 or more
antihypertensives including a conventional diuretic. Such patients
commonly respond to mineralocorticoid receptor blockade with
major (~30 mm SBP) falls in blood pressure. It has long been
suspected that those patients may constitute a “pre-primary aldoste-
ronism” group, perhaps progressing to frank primary aldosteronism
over time. An alternative possibility is that such patients in fact do
have autonomous aldosterone secretion, but are missed reﬂecting the
current lack of deﬁnition in terms of assay variability, arbitrary cut-off
levels, and the conservative interpretation of conﬁrmatory/exclusion
tests. Such patients may also be overlooked on screening, due to the
confounding effects on plasma levels of renin and aldosterone of
antihypertensive medications which the patient or physician is
unwilling to withdraw in severe hypertension.
In terms of aldosterone as a risk factor in primary aldosteronism, it
is important to say at the outset that the cardiovascular sequelae are
not merely a reﬂection of raised blood pressure (while they may
indeed be a consequence of increased sodium retention: vide infra).
There have been a number of studies examining aldosterone as a
cardiovascular risk factor in primary aldosteronism: two will be cited
in extenso, as representing the opposite poles of aldosterone excess.
Stowasser et al. [25] compared 8 patients with familial hyperaldos-
teronism type 1 (FHI: glucocorticoid remediable hyperaldosteronism)
in whom blood pressure was not yet elevated above normal with 24
age-, sex- and blood pressure-matched controls, and showed clear
evidence of cardiovascular damage in the patients with very modestly
elevated aldosterone levels. Milliez et al. [26] examined patients at the
other end of the spectrum, with established primary aldosteronism
and clearly elevated blood pressure. Again compared with age-, sex-
and blood pressure-matched essential hypertensives, the primary
aldosteronism patients showed a twelve-fold higher incidence of
atrial ﬁbrillation, a six-fold higher incidence of myocardial infarction,and a four-fold higher incidence of stroke. In this study 124 patients
with primary aldosteronism were compared with 465 essential
hypertensives; aldosterone levels were 2- to 3-fold higher in the
primary aldosteronism group, and active plasma renin and plasma
potassium signiﬁcantly lower, as might be expected.
The unexpected ﬁnding in the Milliez et al. study was a highly
signiﬁcantly different level in total cholesterol, with a value of 5.4 ±
0.9mmol/l in primary aldosteronism and 5.9 ± 1.1 in essential
hypertension; serum glucose, in contrast, was equivalent between the
two groups (6.0 ± 1.3, 5.9 ± 1.9 mmol/l). These two values would
thus not support a role for elevated levels of aldosterone per se in the
metabolic syndrome; subsequent studies have demonstrated an
association, although whether the hyperaldosteronism in these
subjects with manifestations of the metabolic syndrome is autoch-
thonous as well as autonomous (in terms of the classic stimuli to
aldosterone secretion) is uncertain. Krug and Ehrhart-Bornstein [27],
for example, postulate that hypersecretion of trophic factors from
abdominal adipocytes results in aldosterone secretion, outside the
normal renin/angiotensin/sodium/potassium feed back loop, leading
to hypertension and cardiovascular disease, and possibly to dyslipi-
daemia and altered glucose homeostasis.
This postulate follows a range of population-based studies in
which aldosterone and the metabolic syndrome have been associated.
In an early study on subjects of African origin in the Seychelles,
Bochud et al. [28] showed aldosterone levels to be positively
correlated with the metabolic syndrome, with blood pressure
elevation in older individuals, and with waist circumference in men:
a negative correlation between aldosterone levels and those of HDL-C
was also found. Kidambi et al. [29], in a cross-sectional study on
African Americans, similarly showed that in subjects with the
metabolic syndrome aldosterone levels were higher and were
positively correlated with blood pressure, waist circumference and
insulin resistance. In a third cross-sectional study, Colussi et al. [30]
showed a direct relationship between aldosterone levels, insulin
resistance and hyperinsulinaemia in a cohort of Caucasian subjects.
In these three cross-sectional studies subject numbers were
respectively 356, 397 and 458; in a longitudinal study of 2292
subjects from the Framingham cohort, Ingelsson et al. [31] again
reported aldosterone to be positively associated with an increase over
time in blood pressure, and inversely with HDL-C levels. In addition,
they reported that higher circulating aldosterone levels were
associated with the development of the metabolic syndrome, and
longitudinal change in its component pathologies, consistent with a
causative rather than a collateral role in aetiology.
Currently, two large studies (total n = 6300) in Germany are
tracking the relationship between aldosterone and the metabolic
syndrome, SHIP (Study of Health in Pomerania) in north-eastern
Germany and KORA (Kooperative Gesundheitsforschung in der
Region Augsburg) in Bavaria. The results for women are quite
different between the two locales, but those for men less so. The
assays for both studies were performed centrally, and the reason(s)
for the differences are presently unclear. What SHIP and KORA do,
however, is to sound a note of caution re extrapolating from one study
alone to the population as a whole.
In a more recent case control study [32], patients from the German
Conn's Registry were age-, sex-, BMI- and blood pressure-matched
with hypertensive controls from the KORA study in Bavaria. The
prevalence of diabetes in the patients with primary aldosteronism
was N 50% higher than in the control hypertensive group, across all
patients and in those with a BMI b 30. Similar results, however, had
not been seen in previous cross-sectional studies [33–35]. In the ﬁrst
of these, Widimsky et al. [33] reported prevalence rates of diabetes
mellitus (20%/14%) and of impaired glucose tolerance (18%/10%) to be
higher in primary aldosteronism than essential hypertension, without
reaching statistical signiﬁcance, probably reﬂecting the small number
of patients studied (36 vs. 21). Catena et al. [34] compared 47 patients
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found no difference in area under the curves for glucose and insulin.
Matrazova et al. [35], in a much larger study, compared 460 patients
with primary aldosteronism with 1363 essential hypertensives, and
found no difference in incidence of diabetes (17% vs. 14%), and a
counterintuitive increase in impaired glucose tolerance in the essential
hypertensives (26%/33%); again, the differences in statistically
signiﬁcant ﬁndings between studies sound a note of caution.
The mechanisms whereby aldosterone might play a causative role
in impaired glucose tolerance/insulin resistance/diabetes remain
lightly explored. Giachetti et al. [36] have suggested that a variety of
effects may be in play—that aldosterone excess may reduce both the
expression and afﬁnity of insulin receptors in adipocytes, as well as
down regulating adipocyte glucose transporters, a process abetted by
the effect of hypokalaemia to lower insulin secretion from the
pancreas, and possible deleterious effects of aldosterone-induced
ﬁbrosis in both pancreas and adipocytes. The adipocyte effects are
extrapolated from single in vitro studies, and the extent to which
similar mechanisms may operate in vivo remains to be determined.
3. Aldosterone and the brain
It has been relatively recently recognized that mental illnesses,
particularly anxiety disorder and depression, constitute a major
cardiovascular risk factor. Major depression, for example, is associated
with twice the chance of myocardial infarction, and twice the chance
of a fatal outcome [37]. In this context there have been a number of
reports of an association between plasma aldosterone concentration
and depression. Over 30 years ago Malinov et al. [38] reported that
episodes of depression led to the diagnosis of primary aldosteronism,
an observation subsequently conﬁrmed by others [39,40]; recently,
Sonino et al. [41] reported the increased incidence of anxiety
disorders in patients with primary aldosteronism. In parallel, a
range of studies [42,43] have reported increased plasma aldosterone
levels in depressed patients, compared with the range seen in healthy
controls. Most recently, Stowasser et al. [44] in a small study on 22
patients reported that patients with conﬁrmed adrenal adenoma
scored low in the SF-36 questionnaire (a self-perception index of
quality of life), with signiﬁcant improvement across a range of
parameters at both 3 and 6 months post-adrenalectomy. Taken
together, those studies suggest a possibly important association of
aldosterone and depression in depressed patients, and in addition a
signiﬁcant association of increased anxiety, depression and somatic
symptoms in primary aldosteronism, relieved by adrenalectomy. The
extent to which successful alleviation of depression is reﬂected in
normalization of plasma aldosterone levels is yet to be systematically
explored. Similarly, whether the increased aldosterone levels are
causative of or collateral with the increased cardiovascular risk in
mental illness remains to be established.
4. Essential hypertension and heart failure
In neither essential hypertension nor heart failure is increased
aldosterone secretion autonomous, and there are no data that would
support aldosterone as a primary driver in either condition. In both
conditions although raised aldosterone levels are often regarded as a
risk factor, such an elevation is more correctly a response to the
severity of the disease or to treatment intervention, rather than a risk
factor with a primary role in disease progression. In essential
hypertension there is clear evidence that mineralocorticoid receptor
blockade can substantially lower blood pressure in ~ 80% of patients
[45], as there is for the beneﬁcial effects of mineralocorticoid receptor
blockade in heart failure [46,47]. The undisputed effectiveness of
mineralocorticoid receptor blockade in these conditions is commonly
translated as evidence for a deleterious effect of aldosterone rather
than of mineralocorticoid receptor activation. The clinical study citedabove [45] clearly distinguished the anti-hypertensive and electrolyte
effects of mineralocorticoid receptor blockade, over a range of
antagonist doses, and very recently Mihailidou et al. [23] have
shown that in experimental myocardial infarction low levels of
cortisol mimic aldosterone in activating cardiomyocyte mineralocor-
ticoid receptors and aggravating tissue damage.
Recent clinical studies would similarly suggest caution in ascribing
risk factor status to aldosterone per se in progressive heart failure.
Guder et al. [48], in a prospective cohort study of 294 consecutive
patients with progressive heart failure and 27% mortality at a median
follow-up of 803 days, showed that both aldosterone and cortisol
levels were independent predictors of increasedmortality. The hazard
ratio for the highest versus the lowest tertile for cortisol was 2.72 (95%
CL 1.38–5.36, pb0.004) and for aldosterone 2.19 (95% CL 1.23–3.93,
pb0.008). In a subsequent study on a similar sized cohort (319),
Yamaji et al. [49] showed–in patients with a lower event rate (9%) at a
mean of 33 months–that serum cortisol levels were an independent
predictor of cardiac events, but those of aldosterone were not. Again,
the studies addressed different populations with different outcomes
in terms of mortality, but in each cortisol would appear to be a better
predictor of outcome–and possibly thus more of a risk factor–than
aldosterone.
5. Aldosterone, the enigma
Put simply, the enigma is this: In chronic sodium deﬁciency,
plasma aldosterone levels reach very high levels, capable of reducing
urinary sodium excretion to 2–3 meq/day. In such subjects available
epithelial mineralocorticoid receptors are fully aldosterone-occupied
and -activated, and in non-epithelial tissues (e.g. cardiomyocytes) to
presumably a considerably higher percentage than the normal ~ 1%
occupancy when levels of aldosterone and cortisol are in the normal
range. Despite such high levels subjects have neither blood pressure
elevation nor any signs of cardiovascular damage: the elevated levels
of aldosterone are thus homeostatic in the context of sodium
deﬁciency, and when sodium status is appropriate such levels are
not a cardiovascular risk. Contrast this with primary aldosteronism,
where hormone levels may be considerably lower, but result in
cardiovascular damage. In both epithelial and nonepithelial tissues a
lower number of mineralocorticoid receptors will be occupied and
activated than in chronic sodium deﬁciency, but the effects seen are
much more pronounced.
The answer at one level has been known for decades to be sodium
status. In mineralocorticoid/salt models of hypertension, administra-
tion of aldosterone or deoxycorticosterone to animals on a very low
sodium intake neither raises blood pressure nor causes cardiac
damage. In animals systematically administered aldosterone but
with their blood pressure clamped to normal levels by the
intracerebroventricular administration of the mineralocorticoid re-
ceptor antagonist RU28318, the extent of cardiovascular damage is
the same as in aldosterone/salt animals infused ICV with vehicle—i.e.
the cardiovascular damage represents a direct mineralocorticoid/salt
interaction, not one mediated via elevation of blood pressure [50].
One possible scenario yoking aldosterone and sodium status into
cardiovascular damage mode (including blood pressure elevation) is
the secretion of endogenous ouabain from the adrenal zona
glomerulosa [51]. Whereas aldosterone secretion rates are very low,
those of endogenous ouabain are an order of magnitude lower. The
biosynthetic pathway for aldosterone production is well-character-
ized, although the recent study on Cry null mice [52] would appear to
add 3βhydroxysteroid dehydrogenase to side chain cleavage enzyme
and aldosterone synthase as rate-limiting enzymes: the biosynthetic
pathway for endogenous ouabain synthesis is much less well
established. For aldosterone ACTH is a stimulus independent of ﬂuid
and electrolyte status, responsible for its circadian variation; for
endogenous ouabain ACTH is a major stimulus, and ACTH-induced
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binding site on theα2 subunit of the sodium/potassium ATPase, or by
infusion into wild-type mice of the blocking antibody digibind [53].
Angiotensin is a primary stimulus for aldosterone secretion, acting via
AT1 receptors; angiotensin also regulates the secretion of endogenous
ouabain, but via the 10-fold lower afﬁnity AT2 receptors [54]. Where
the two products are polar opposites is in their response to sodium
status. Aldosterone secretion is raised in response to sodium
deﬁciency: secretion of endogenous ouabain is raised in response to
sodium loading [55]. The physiological role of aldosterone is to retain
sodium in the face of chronic deﬁciency; that of endogenous ouabain
presumably to dump sodium, via a pressure natriuresis, in sodium
loading.
Given the documented effects of endogenous ouabain to raise
blood pressure, it is possible that the blood pressure elevating effects
of aldosterone reﬂect not only direct effects on the vessel wall but also
sodium retention with the resultant elevation of endogenous ouabain
secretion. This may be seen as a gloss on the current teaching that
aldosterone raises blood pressure via increasing circulatory volume,
resulting in increased cardiac output followed by reﬂex vasoconstric-
tion to normalise cardiac output. In fact it is not, in that it introduces a
second hormone of adrenal cortical origin as a key mediator of the
response to inappropriate aldosterone levels for sodium status, rather
than a cascade of mechanical/neural responses.
The combined elevation of aldosterone and endogenous ouabain
levels in response to salt/mineralocorticoid imbalance may thus be an
explanation of the hypertension produced; as noted previously,
however, in both primary aldosteronism and mineralocorticoid/salt
experimental models excess aldosterone produces cardiovascular
sequelae over and above those due to elevated blood pressure alone.
Given that this is the case, any contribution of endogenous ouabain to
the status of aldosterone as a marker of cardiovascular risk requires
demonstration of at least additive effects in terms of vascular con-
tractility or cardiac cell damage. Such studies are yet to be attempted.
6. ENVOI
Aldosterone is clearly a cardiovascular risk factor in primary
aldosteronism. Given that aldosterone levels are incompletely sup-
pressed by chronic high salt intake, it may be that even low normal
levels are a hidden risk factor in cardiovascular disease. In both these
situations aldosterone levels are inappropriate for sodium status. The
extensionof risk factor status to aldosterone in cardiovascular disease to
essential hypertension and heart failure is primarily based on the
efﬁcacy of mineralocorticoid receptor blockade in these conditions.
Evidence, both experimental and clinical, is building that in these
circumstances it is cortisol which activates mineralocorticoid receptors,
in the context of tissue damage, to aggravate the extent of the tissue
damage and accelerate the progression of functional decline: mineral-
ocorticoid receptor activation, not aldosterone, is the risk factor.
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